David B Savage

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi PPAR gamma as a metabolic regulator: insights from genomics and pharmacology
    David B Savage
    Department of Medicine, University of Cambridge, UK
    Expert Rev Mol Med 7:1-16. 2005
  2. doi Lipodystrophy: metabolic insights from a rare disorder
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK
    J Endocrinol 207:245-55. 2010
  3. doi Metabolic insights from extreme human insulin resistance phenotypes
    Anna Stears
    Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge, UK
    Best Pract Res Clin Endocrinol Metab 26:145-57. 2012
  4. ncbi The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation
    Mark Gurnell
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge CB2 2QQ, United Kingdom
    J Clin Endocrinol Metab 88:2412-21. 2003
  5. ncbi Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma
    Maura Agostini
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, United Kingdom
    Endocrinology 145:1527-38. 2004
  6. doi Human congenital perilipin deficiency and insulin resistance
    Kristina Kozusko
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Endocr Dev 24:150-5. 2013
  7. ncbi Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
    David B Savage
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Diabetes 52:910-7. 2003
  8. doi Mouse models of inherited lipodystrophy
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Dis Model Mech 2:554-62. 2009
  9. doi Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Curr Opin Lipidol 21:329-36. 2010
  10. doi Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance
    Robert K Semple
    Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Diabetes Care 31:977-9. 2008

Collaborators

Detail Information

Publications25

  1. ncbi PPAR gamma as a metabolic regulator: insights from genomics and pharmacology
    David B Savage
    Department of Medicine, University of Cambridge, UK
    Expert Rev Mol Med 7:1-16. 2005
    ....
  2. doi Lipodystrophy: metabolic insights from a rare disorder
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK
    J Endocrinol 207:245-55. 2010
    ....
  3. doi Metabolic insights from extreme human insulin resistance phenotypes
    Anna Stears
    Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge, UK
    Best Pract Res Clin Endocrinol Metab 26:145-57. 2012
    ....
  4. ncbi The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation
    Mark Gurnell
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge CB2 2QQ, United Kingdom
    J Clin Endocrinol Metab 88:2412-21. 2003
    ..These studies provide further support for the future development of more selective receptor modulators, targeting specific pathways to ameliorate facets of the metabolic syndrome...
  5. ncbi Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma
    Maura Agostini
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, United Kingdom
    Endocrinology 145:1527-38. 2004
    ..Having shown that rosiglitazone is of variable and limited efficacy in these subjects, we suggest that TAs may represent a more rational therapeutic approach...
  6. doi Human congenital perilipin deficiency and insulin resistance
    Kristina Kozusko
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Endocr Dev 24:150-5. 2013
    ..They also suggest that lipolytic inhibitors may be therapeutically useful in these patients...
  7. ncbi Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
    David B Savage
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Diabetes 52:910-7. 2003
    ..Although the condition is rare, the study of humans with dominant-negative mutations in PPAR-gamma can provide important insight into the roles of this nuclear receptor in human metabolism...
  8. doi Mouse models of inherited lipodystrophy
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Dis Model Mech 2:554-62. 2009
    ....
  9. doi Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Curr Opin Lipidol 21:329-36. 2010
    ..To summarize recent research into the mechanisms linking insulin resistance, nonalcoholic fatty liver disease and metabolic dyslipidaemia...
  10. doi Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance
    Robert K Semple
    Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Diabetes Care 31:977-9. 2008
    ..Our previous observation of paradoxical hyperadiponectinemia in insulin receptoropathy provides a possible basis for a simpler and cheaper screening test...
  11. ncbi A clinical approach to severe insulin resistance
    David B Savage
    Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
    Endocr Dev 11:122-32. 2007
    ..In the absence of a specific diagnosis and therapy, metformin is a useful insulin sensitizer and should be used in conjunction with aggressive diet and exercise interventions...
  12. ncbi Congenital syndromes of severe insulin resistance
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, UK
    Pediatr Endocrinol Rev 8:190-9. 2011
    ..Here we review the general and specific features of syndromes of severe IR, summarise their classification, and recommend strategies for their subsequent investigation...
  13. ncbi Digenic inheritance of severe insulin resistance in a human pedigree
    David B Savage
    Department of Clinical Biochemistry, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Nat Genet 31:379-84. 2002
    ....
  14. pmc Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity
    Cheol Soo Choi
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 104:16480-5. 2007
    ..Taken together with previous work demonstrating that Acc2(-/-) mice have a normal lifespan, these data suggest that Acc2 inhibition is a viable therapeutic option for the treatment of obesity and type 2 diabetes...
  15. ncbi Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization
    Terry P Combs
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Endocrinology 143:998-1007. 2002
    ..Furthermore, Acrp30 is likely to be a biomarker of in vivo PPARgamma activation...
  16. ncbi Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma
    Ulf Riserus
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, UK
    Diabetes 54:1379-84. 2005
    ..The restored SCD activity index after rosiglitazone in PPARgamma mutation supports a pivotal role of PPARgamma function in SCD regulation...
  17. pmc The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
    Kitt Falk Petersen
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06536, USA
    Proc Natl Acad Sci U S A 104:12587-94. 2007
    ....
  18. ncbi Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy
    Edward D Javor
    National Institute of Diabetes and Digestive and Kidney Diseases NIH, 10 Center Drive, Room 8D20, Bethesda, MD 20892 1770, USA
    J Clin Endocrinol Metab 89:3199-207. 2004
    ..The majority treated with recombinant leptin demonstrated reduction in proteinuria and hyperfiltration...
  19. ncbi Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy
    David B Savage
    Department of Clinical Biochemistry and Medicine, Level 4, Box 232, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, United Kingdom
    J Clin Endocrinol Metab 90:1446-52. 2005
    ..Insight into the molecular mechanisms responsible for this phenomenon may yield novel therapeutic approaches for obesity...
  20. ncbi Mechanisms of insulin resistance in humans and possible links with inflammation
    David B Savage
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06510, USA
    Hypertension 45:828-33. 2005
    ..Understanding the molecular/biochemical defects responsible for insulin resistance is beginning to unveil novel therapeutic targets for treatment of the metabolic syndrome and type 2 diabetes...
  21. pmc Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
    David B Savage
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Invest 116:817-24. 2006
    ..These studies suggest that pharmacological inhibition of Acc1 and -2 may be a novel approach in the treatment of NAFLD and hepatic insulin resistance...
  22. pmc TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population
    Ruth J F Loos
    Medical Research Council Epidemiology Unit, Strangeways Research Laboratory, Cambridge, UK
    Diabetes 56:1943-7. 2007
    ....
  23. pmc A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice
    David B Savage
    Department of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, United Kingdom
    PLoS Med 5:e27. 2008
    ..However, the functional implications of the mutation were not known. The objective of this study was to characterise the molecular and physiological consequences of this genetic variant...
  24. ncbi Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
    Cheol Soo Choi
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Biol Chem 282:22678-88. 2007
    ....
  25. pmc Disordered lipid metabolism and the pathogenesis of insulin resistance
    David B Savage
    Department of Internal Medicine, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06536 8012, USA
    Physiol Rev 87:507-20. 2007
    ..in 2004, we will concentrate on human studies involving the use of isotopes and/or magnetic resonance spectroscopy, occasionally drawing on mouse models which provide additional mechanistic insight...